{"protocolSection": {"identificationModule": {"nctId": "NCT04752475", "orgStudyIdInfo": {"id": "AAAT2525"}, "organization": {"fullName": "Columbia University", "class": "OTHER"}, "briefTitle": "Lasix for the Prevention of De Novo Postpartum Hypertension", "officialTitle": "Lasix for the Prevention of De Novo Postpartum Hypertension: A Randomized Controlled Trial (LAPP Trial)", "acronym": "LAPP"}, "statusModule": {"statusVerifiedDate": "2023-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-10-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-04-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-05-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-02-08", "studyFirstSubmitQcDate": "2021-02-09", "studyFirstPostDateStruct": {"date": "2021-02-12", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-04-18", "resultsFirstSubmitQcDate": "2023-04-18", "resultsFirstPostDateStruct": {"date": "2023-05-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-04-18", "lastUpdatePostDateStruct": {"date": "2023-05-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Russell Miller", "investigatorTitle": "Sloane Hospital for Women Associate Professor of Prenatal Pediatrics (in Obstetrics and Gynecology)", "investigatorAffiliation": "Columbia University"}, "leadSponsor": {"name": "Columbia University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high-risk women.\n\nSecondary objectives: To evaluate whether oral furosemide administered to high-risk women after delivery can reduce the frequency of postpartum hypertensive episodes, the need for antihypertensive therapy, the risk of postpartum preeclampsia, and the incidence of severe maternal morbidity.", "detailedDescription": "Hypertensive disorders of pregnancy are one of the leading causes of maternal morbidity and mortality worldwide. The majority of clinical research has focused on pregnancy-related hypertension that develops in the antenatal period, while studies of the incidence, risk factors, and prevention of postpartum hypertension are limited. In particular, there is a paucity of data about the clinical entity known as de novo postpartum hypertension, in which women who are normotensive throughout pregnancy and delivery subsequently go on to develop high blood pressure in the immediate to late postpartum period. Of those with postpartum preeclampsia, 33-69% were normotensive antepartum.\n\nEarly identification and treatment of antepartum preeclampsia has been shown to decrease some severe maternal outcomes. Conversely, women with de novo postpartum hypertensive disorders remain among the highest risk for severe maternal morbidity due to decreased surveillance and lack of data regarding preventive therapies and interventions. Evidence from multiple randomized controlled trials have demonstrated a benefit in the use of oral loop-diuretics in decreasing postpartum systolic blood pressure, promoting faster normalization of blood pressure, and decreasing the need for antihypertensive therapy in women with an antenatal diagnosis of preeclampsia. Biological plausibility suggests that loop-diuretic therapy may similarly mitigate the normal physiologic mechanism that has been implicated in the pathogenesis of hypertensive complications after delivery in women at risk for de novo postpartum hypertension.\n\nThis study is a double-blind randomized placebo-controlled trial of 82 high-risk women to assess whether treatment with oral Lasix (furosemide) after delivery reduces blood pressure at the time of discharge. Women at high risk for de novo postpartum hypertension will be randomized to a five-day course of either 20 mg oral Lasix (furosemide) or placebo once daily initiated after delivery. Women will be monitored through their routine 2-week and 6-week postpartum visits, during which times hypertensive complications and adverse effects of therapy will be assessed."}, "conditionsModule": {"conditions": ["Postpartum Pregnancy-Induced Hypertension", "Postpartum Preeclampsia", "Hypertension, Pregnancy-Induced", "Hypertension"], "keywords": ["De novo postpartum hypertension", "New-onset postpartum hypertension", "Lasix", "Furosemide"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The study is a randomized controlled clinical trial of 82 women with one or more high-risk factors for de novo postpartum hypertension, randomized to one of two arms: 20 mg PO Lasix (furosemide) daily for 5 days or identical-appearing daily placebo for 5 days.", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "TRIPLE", "maskingDescription": "Consenting women will be assigned to Lasix (furosemide) or placebo in a 1:1 ratio according to a randomization scheme achieved using a computer generated algorithm. Neither the participant nor the clinical care team will be aware of the allocation arm.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 82, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lasix (furosemide)", "type": "EXPERIMENTAL", "description": "Furosemide 20 mg, oral, once daily for 5 days", "interventionNames": ["Drug: Furosemide"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Identical-appearing placebo, oral, once daily for 5 days", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Furosemide", "description": "Furosemide 20 mg pill taken daily for 5 days", "armGroupLabels": ["Lasix (furosemide)"], "otherNames": ["Lasix"]}, {"type": "OTHER", "name": "Placebo", "description": "Identical-appearing placebo pill taken daily for 5 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Arterial Blood Pressure (MAP)", "description": "Difference in MAP averaged over the 24 hours prior to discharge or the 24 hours prior to antihypertensive therapy initiation (whichever occurs first)", "timeFrame": "24 hours prior to discharge through discharge, up to 7 days"}], "secondaryOutcomes": [{"measure": "Rate of de Novo Postpartum Preeclampsia", "description": "Proportion of participants who develop de novo postpartum hypertension", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum"}, {"measure": "Frequency of Hypertensive Episodes", "description": "Mean frequency of recorded blood pressures that are elevated (\\>140 systolic OR \\>90 diastolic)", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum"}, {"measure": "Rate of Magnesium Sulfate Administration", "description": "Proportion of participants who receive intravenous magnesium sulfate for seizure prophylaxis", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum"}, {"measure": "Rate of Initiation of Antihypertensives", "description": "Proportion of participants receiving intravenous antihypertensive therapy and initiated on oral hypertensive therapy", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum"}, {"measure": "Time to Discharge", "description": "Time until discharge from the hospital", "timeFrame": "Randomization through discharge, up to 7 days"}, {"measure": "Rate of Severe Maternal Morbidity", "description": "Proportion of participants experiencing severe maternal morbidity (e.g. seizure, stroke, Posterior reversible encephalopathy syndrome (PRES), death, etc.)", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum"}, {"measure": "Frequency of Triage or Emergency Department (ED) Presentation/Readmission", "description": "Mean frequency of triage or ED presentation/readmission for hypertensive-related complaints", "timeFrame": "2 weeks postpartum, 6 weeks postpartum"}, {"measure": "Breastfeeding Continuation Rate", "description": "Proportion of participants continuing to breastfeed of those who initiated breastfeeding after delivery", "timeFrame": "2 weeks postpartum, 6 weeks postpartum"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Postpartum women\n* No antenatal diagnosis of hypertensive disorder of pregnancy at the time of admission for delivery, defined as existing chronic hypertension diagnosis or documented blood pressure of \u2265140 systolic OR \u226590 diastolic on at least 2 occasions at least 4 hours apart prior to delivery admission who do not go on to get magnesium for seizure prophylaxis by the time of delivery\n* At least 18 years of age\n* English or Spanish speakers\n* One or more high risk factors for development of de novo postpartum hypertension\n\nExclusion Criteria:\n\n* Non-English or Spanish speakers\n* Women with a contraindication to diuretic therapy\n* Women who have used diuretics in the two weeks prior to delivery", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Russell S. Miller, MD", "affiliation": "Columbia University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Columbia University Irving Medical Center", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "referencesModule": {"references": [{"pmid": "18455140", "type": "BACKGROUND", "citation": "Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008 Jul;199(1):36.e1-5; discussion 91-2. e7-11. doi: 10.1016/j.ajog.2008.03.007. Epub 2008 May 2."}, {"pmid": "30575675", "type": "BACKGROUND", "citation": "ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1. doi: 10.1097/AOG.0000000000003018."}, {"pmid": "21979459", "type": "BACKGROUND", "citation": "Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet Gynecol. 2011 Nov;118(5):1102-1107. doi: 10.1097/AOG.0b013e318231934c."}, {"pmid": "21740315", "type": "BACKGROUND", "citation": "Filetti LC, Imudia AN, Al-Safi Z, Hobson DT, Awonuga AO, Bahado-Singh RO. New onset delayed postpartum preeclampsia: different disorders? J Matern Fetal Neonatal Med. 2012 Jul;25(7):957-60. doi: 10.3109/14767058.2011.601365. Epub 2011 Aug 16."}, {"pmid": "15167870", "type": "BACKGROUND", "citation": "Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol. 2004 May;190(5):1464-6. doi: 10.1016/j.ajog.2004.02.037."}, {"pmid": "15684172", "type": "BACKGROUND", "citation": "Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005 Feb;105(2):402-10. doi: 10.1097/01.AOG.0000152351.13671.99."}, {"pmid": "8134057", "type": "BACKGROUND", "citation": "Lubarsky SL, Barton JR, Friedman SA, Nasreddine S, Ramadan MK, Sibai BM. Late postpartum eclampsia revisited. Obstet Gynecol. 1994 Apr;83(4):502-5. doi: 10.1097/00006250-199404000-00003."}, {"pmid": "24211478", "type": "BACKGROUND", "citation": "Bigelow CA, Pereira GA, Warmsley A, Cohen J, Getrajdman C, Moshier E, Paris J, Bianco A, Factor SH, Stone J. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. Am J Obstet Gynecol. 2014 Apr;210(4):338.e1-338.e8. doi: 10.1016/j.ajog.2013.11.004. Epub 2013 Nov 7."}, {"pmid": "12066093", "type": "BACKGROUND", "citation": "Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol. 2002 Jun;186(6):1174-7. doi: 10.1067/mob.2002.123824."}, {"pmid": "15625138", "type": "BACKGROUND", "citation": "Ascarelli MH, Johnson V, McCreary H, Cushman J, May WL, Martin JN Jr. Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstet Gynecol. 2005 Jan;105(1):29-33. doi: 10.1097/01.AOG.0000148270.53433.66."}, {"pmid": "27835048", "type": "BACKGROUND", "citation": "Veena P, Perivela L, Raghavan SS. Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial. Hypertens Pregnancy. 2017 Feb;36(1):84-89. doi: 10.1080/10641955.2016.1239735. Epub 2016 Nov 11."}, {"type": "BACKGROUND", "citation": "Perdigao JL, Lewey J, Hirshberg A, et al. LB 4: Furosemide for Accelerated Recovery of Blood Pressure Postpartum: a randomized placebo controlled trial (FoR BP). American Journal of Obstetrics & Gynecology. 2020;222(1):S759-S760."}, {"pmid": "8796794", "type": "BACKGROUND", "citation": "Atterbury JL, Groome LJ, Hoff C. Blood pressure changes in normotensive women readmitted in the postpartum period with severe preeclampsia/eclampsia. J Matern Fetal Med. 1996 Jul-Aug;5(4):201-5. doi: 10.1002/(SICI)1520-6661(199607/08)5:43.0.CO;2-O."}, {"pmid": "29703800", "type": "BACKGROUND", "citation": "Hirshberg A, Downes K, Srinivas S. Comparing standard office-based follow-up with text-based remote monitoring in the management of postpartum hypertension: a randomised clinical trial. BMJ Qual Saf. 2018 Nov;27(11):871-877. doi: 10.1136/bmjqs-2018-007837. Epub 2018 Apr 27."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Lasix (Furosemide)", "description": "Furosemide 20 mg, oral, once daily for 5 days\n\nFurosemide: Furosemide 20 mg pill taken daily for 5 days"}, {"id": "FG001", "title": "Placebo", "description": "Identical-appearing placebo, oral, once daily for 5 days\n\nPlacebo: Identical-appearing placebo pill taken daily for 5 days"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Data collected and analyzed for 80 of the 82 participants - 2 participants who initially consented to participate in the trial subsequently withdrew prior to discharge from delivery hospitalization.", "groups": [{"id": "BG000", "title": "Lasix (Furosemide)", "description": "Furosemide 20 mg, oral, once daily for 5 days\n\nFurosemide: Furosemide 20 mg pill taken daily for 5 days"}, {"id": "BG001", "title": "Placebo", "description": "Identical-appearing placebo, oral, once daily for 5 days\n\nPlacebo: Identical-appearing placebo pill taken daily for 5 days"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "80"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "age < 35", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "29"}]}]}, {"title": "age >= 35", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "51"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "80"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "49"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "10"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "25"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "80"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Arterial Blood Pressure (MAP)", "description": "Difference in MAP averaged over the 24 hours prior to discharge or the 24 hours prior to antihypertensive therapy initiation (whichever occurs first)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "24 hours prior to discharge through discharge, up to 7 days", "groups": [{"id": "OG000", "title": "Lasix (Furosemide)", "description": "Furosemide 20 mg, oral, once daily for 5 days\n\nFurosemide: Furosemide 20 mg pill taken daily for 5 days"}, {"id": "OG001", "title": "Placebo", "description": "Identical-appearing placebo, oral, once daily for 5 days\n\nPlacebo: Identical-appearing placebo pill taken daily for 5 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.9", "spread": "7.4"}, {"groupId": "OG001", "value": "86.8", "spread": "7.1"}]}]}]}, {"type": "SECONDARY", "title": "Rate of de Novo Postpartum Preeclampsia", "description": "Proportion of participants who develop de novo postpartum hypertension", "reportingStatus": "NOT_POSTED", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Frequency of Hypertensive Episodes", "description": "Mean frequency of recorded blood pressures that are elevated (\\>140 systolic OR \\>90 diastolic)", "reportingStatus": "NOT_POSTED", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Rate of Magnesium Sulfate Administration", "description": "Proportion of participants who receive intravenous magnesium sulfate for seizure prophylaxis", "reportingStatus": "NOT_POSTED", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Rate of Initiation of Antihypertensives", "description": "Proportion of participants receiving intravenous antihypertensive therapy and initiated on oral hypertensive therapy", "reportingStatus": "NOT_POSTED", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Time to Discharge", "description": "Time until discharge from the hospital", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through discharge, up to 7 days", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Rate of Severe Maternal Morbidity", "description": "Proportion of participants experiencing severe maternal morbidity (e.g. seizure, stroke, Posterior reversible encephalopathy syndrome (PRES), death, etc.)", "reportingStatus": "NOT_POSTED", "timeFrame": "Discharge (up to 7 days), 2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Frequency of Triage or Emergency Department (ED) Presentation/Readmission", "description": "Mean frequency of triage or ED presentation/readmission for hypertensive-related complaints", "reportingStatus": "NOT_POSTED", "timeFrame": "2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Breastfeeding Continuation Rate", "description": "Proportion of participants continuing to breastfeed of those who initiated breastfeeding after delivery", "reportingStatus": "NOT_POSTED", "timeFrame": "2 weeks postpartum, 6 weeks postpartum", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 6 weeks postpartum", "eventGroups": [{"id": "EG000", "title": "Lasix (Furosemide)", "description": "Furosemide 20 mg, oral, once daily for 5 days\n\nFurosemide: Furosemide 20 mg pill taken daily for 5 days", "deathsNumAffected": 0, "deathsNumAtRisk": 40, "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 0, "otherNumAtRisk": 40}, {"id": "EG001", "title": "Placebo", "description": "Identical-appearing placebo, oral, once daily for 5 days\n\nPlacebo: Identical-appearing placebo pill taken daily for 5 days", "deathsNumAffected": 0, "deathsNumAtRisk": 40, "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 0, "otherNumAtRisk": 40}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Russell Miller, MD", "organization": "Associate Professor of Prenatal Pediatrics at CUIMC", "email": "rsm20@cumc.columbia.edu", "phone": "212-305-3151"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2022-06-22", "uploadDate": "2023-04-13T14:36", "filename": "Prot_SAP_000.pdf", "size": 738000}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000011225", "term": "Pre-Eclampsia"}, {"id": "D000046110", "term": "Hypertension, Pregnancy-Induced"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000011248", "term": "Pregnancy Complications"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M14106", "name": "Pre-Eclampsia", "asFound": "Preeclampsia", "relevance": "HIGH"}, {"id": "M25635", "name": "Hypertension, Pregnancy-Induced", "asFound": "Hypertension, Pregnancy-Induced", "relevance": "HIGH"}, {"id": "M7633", "name": "Eclampsia", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "T2019", "name": "Eclampsia", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000005665", "term": "Furosemide"}], "ancestors": [{"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049994", "term": "Sodium Potassium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "asFound": "48 hours", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26153", "name": "Sodium Potassium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}